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Consortium for Blood Group Genes (CBGG): 
2009 report
The Consortium for Blood Group Genes is a worldwide organiza-
tion whose goal is to have a vehicle to interact, establish guide-
lines, operate a profi ciency program, and provide education for 
laboratories involved in DNA and RNA testing for the predic-
tion of blood group, platelet, and neutrophil antigens. Current-
ly, the consortium operates with representatives from Brazil, 
Canada, and the United States. Membership is voluntary with 
the expectation that members actively contribute to discussions 
involving blood group genetics. This year witnessed a change 
in the standing committee membership and the institution of 
a representative for the human platelet antigens group. Look-
ing forward, the consortium sees challenges for the nomencla-
ture of blood group alleles and user-required specifi cations for 
laboratory information systems to store genotype information. 
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The Consortium for Blood Group Genes (CBGG) is a not-for-profi t organization established in 2004 by a group of like-minded people with scientifi c or indus-
try experience and interest in the fi eld of the genetics of red 
cell, platelet, and neutrophil antigens, collectively known as 
blood group genetics. The mission of the consortium is “to 
establish guidelines, to provide education, and to provide 
a profi ciency exchange for laboratories involved in DNA or 
RNA testing for the determination of blood group, platelet, 
and neutrophil antigens.” The consortium is coordinated by 
three country representatives: Lilian Castilho (Hemocentro 
de Campinas) for Brazil, Maryse St-Louis (Héma-Québec) 
for Canada, and Connie Westhoff (American Red Cross) 
for the United States, with Marion Reid (New York Blood 
Center) as facilitator and Greg Denomme (BloodCenter of 
Wisconsin) as secretary. Vagner Castro is coordinator for 
the platelet group. Members are encouraged to refer to the 
published CBGG articles for background information and 
progress of the consortium.1–5 Exchange of information is 
mainly accomplished through electronic mailings and a 
yearly meeting, with profi ciency evaluation exercises oc-
curring in the spring and fall of each year.
The CBGG Document
 The CBGG Document is the sole information document 
for members, is made available by electronic transfer, and 
outlines the function of the CBGG. This document contains 
information on the structure, organizational rules and by-
laws, regulatory compliance plan, preferred terminology, 
and progress on the working parties including a summary 
of the profi ciency exchange program (from 2007 to date), 
guidelines of practice, DNA repository, funding, forms and 
disclaimers, and proposed Web site. It is highly recom-
mended that CBGG members refer to this document for the 
aforementioned duties and activities. A meeting is held an-
nually, in part for members to discuss outstanding issues, 
to provide input, to accept amendments, and to summarize 
the profi ciency evaluations.
Regulatory Affairs
 CBGG members continue to recognize the importance 
of appropriately worded reports, including the use of dis-
claimers, of molecular analyses for both blood donors and 
transfusion recipients. Data from molecular testing contin-
ue to be a source of information for the resolution of com-
plex serologic problems, and presently are not intended as 
the sole means for patient transfusion management deci-
sions.
 As an international consortium, CBGG does not provide 
guidance on regulatory affairs; members are responsible for 
knowledge of and compliance with the regulations in their 
own countries. For US members, we bring to your attention 
the Code of Federal Regulations (CFR) Part 864—Hematology 
and Pathology Devices, Subpart E—Specimen Preparation 
Reagents; Sec. 864.4020 Analyte specifi c reagents.
Allele Nomenclature
 The list of target alleles was adopted by the CBGG in 
2007 and updated in 2009. The preferred current termi-
nology is listed under the heading “Target antigen (target 
allele)” in Table 1 of this report. However, the fi nal naming 
of alleles awaits the decision of the International Society for 
Blood Transfusion. When referring to a particular single 
nucleotide change, it is important to follow the designated 
notation, e.g., 125G>A, with intronic nucleotide changes 
represented in the lower case, e.g., –67t>c. The associat-
ed amino acid substitutions fl ank the designated position 
number, e.g., Pro103Ser or P103S. Because gene number-
ing systems vary, and to avoid ambiguity in the location of 
nucleotide changes, the CBGG has adopted GenBank gene 
reference sequences (RefSeqGene) and reference SNP num-
bers (rs#) for blood group genes and nucleotides (Table 1). 
These numbers refer to a set of common documents used 
to communicate or report molecular testing results and are 
linked to other GenBank reference fi les.
Report
G.A. Denomme, C.M Westhoff, L.M. Castilho, M. St-Louis, V. Castro, and M.E. Reid
IMMUNOHEMATOLOGY, Volume 26, Number 2, 201048
Table 1. List of targets and recommended controls for prediction of certain RBC antigens†








Controls and comments (monitor assay perfor-
mance with DNA controls known to be homozy-
gous and heterozygote for both alleles unless 
otherwise noted)
ABO (ABO)                       
001
A (ABO*A1) ABO 
(NG_006669.1)
consensus Targets for nondeletional (261ΔG) ABO*O alleles 
are not listed. Various alleles have been described 
and multiple targets or sequencing is required for 
identification.A2 (ABO*A2) nt 1061ΔC (rs56392308)
B (ABO*B1) nt 526C>G (rs7853989)             
nt 703G>A (rs8176743)             
nt 796C>A (rs8176746)             
nt 803G>C (rs8176747)
O (ABO*O1) nt 261G/ΔG (rs8176719)
















S silenced nt 230C>T, intron 5+5g>t 230T/T not required, I5+5t/t not required
Rh (RH)                             
004
D RHD   
(NG_007494) 
RHDΨ
Exon 4 and 7
 
Exon 4 37-bp insert










CW nt 122A>G 122G/G not required
CX nt 106G>A 106A/A not required
V & VS nt 733C>G (rs1053361) 733G/G not required
V (VS–) nt 1006G>T 1006T/T not required
Lutheran (LU)                    
005
Lua (LU*01 or LU*A)
Lub (LU*02 or LU*B)
LU    
(NG_007480.1)
nt 230A>G (rs28399653)













Duffy (FY)                        
008
Fya (FY*01 or FY*A)
Fyb (FY*02 or FY*B)
FY     
(NG_011626.1)
nt 125G>A (rs12075)
Fyx (FY*265T) nt 265C>T (rs34599082) 265T/T not required
Fy null (RBC) nt -67t>c (rs2814778) GATA nucleotide change
Kidd (JK) 
009
Jka (JK*01 or JK*A)
Jkb (JK*02 or JK*B)
JK     
(NG_011775.1)
nt 838G>A (rs1058396) Testing for nulls may be appropriate in some situ-
ations.
Diego (DI)                         
010
Dia (DI*01 or DI*A)
Dib (DI*02 or DI*B)
DI     
(NG_007498.1)
nt 2561T>C (rs2285644)
Yt (YT)                              
011
Yta (YT*01 or YT*A)
Ytb (YT*02 or YT*B)
YT     
(NG_007474.1)
nt 1057C>A (rs1799805)




SC     
(NG_008749.1)
nt 169G>A (rs56025238) 169A/A not required
Dombrock (DO)                
014
Doa (DO*01 or DO*A)
Dob (DO*02 or DO*B)
DO    
(NG_007477.1)
nt 793A>G (rs11276)
Hy (HY) nt 323G>T (rs28362797)
Joa (JO) nt 350C>T (rs28362798)
Colton (CO)                       
015
Coa (CO*01 or CO*A)
Cob (CO*02 or CO*B)
CO    
(NG_007475.1)
nt 134C>T (rs28362692) 134T/T not required
Landsteiner-Wiener 
(LW) 016
LWa (LW*05 or LW*A)
LWb (LW*07 or LW*B)
LW  
(NG_007728.1)
nt 308A>G 308G/G not required
Cromer (CR)                      
021
Cra (CR*01 or CR*A) CROM  
(NG_007465.1)
nt 679G>C (rs60822373)
Knops (KN)                       
022
Kna (KN*01 or KN*A)
Knb (KN*02 or KN*B)





nt 4768A>G (rs17047660) 4768G/G not required
Sla (KN*04)
Vil (KN*07)
nt 4801A>G (rs17047661) 4801G/G not required
Indian (IN)                          
023
Ina (IN*01 or IN*A)
Inb (IN*02 or IN*B)
IN      
(NG_008937.1)
nt 252C>G
OK (OK)                              
024
Oka (OK*01 or OK*A) OK    
(NG_007468.1)
nt 274G>A Homozygous mutated and heterozygote not 
required
†Predicted antigen negativity should be confirmed by hemagglutination with licensed reagents if available, with unlicensed reagents if available, 
or by a crossmatch performed by the laboratory issuing the product to the patient.
‡Numbering of nucleotide (nt) is based on “A” of AUG
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Guidelines for Molecular Testing
 The CBGG published ISO format guidelines for molec-
ular testing for blood groups in 2007. The AABB standards 
for molecular testing for red cell, platelet, and neutrophil 
antigens was published in 2008.6,7 AABB is currently as-
sembling accreditation guidelines and training accreditors 
to certify laboratories that perform molecular testing for 
red cell, platelet, and neutrophil antigens. The intent of the 
CBGG is to remain as an independent forum and voice for 
molecular testing guidelines in ISO format for use by inter-
national laboratories. The members will update, modify, or 
otherwise amend the CBGG guidelines by process of dis-
cussion and consensus. The CBGG guidelines will not be-
come standards as such to reflect the fact that the CBGG is 
not responsible for laboratory inspection or accreditation.
Proficiency Program
 As of spring 2008, the alleles of RBC antigens for pro-
ficiency exchanges are currently restricted to RHCE*E/
RHCE*e, GYPB*S/GYPB*s, KEL*1/KEL*2, FY*A/FY*B, 
FY*–67C/T GATA, and JK*A/JK*B. The cost of sample 
preparation and shipping the DNA sample is borne in turn 
by each submitting laboratory. To participate in the sam-
ple exchange, proficiency program members must agree 
to provide a sample for distribution in a subsequent year 
through a predetermined rotation. Although participation 
in the CBGG proficiency program mandates that samples 
be discarded after the results have been validated, profi-
ciency program members must ensure they comply with 
the requirements of regulatory bodies. Thus, before join-
ing the proficiency exchange program and committing to 
supplying a sample for the exchange, new members should 
address their institutional requirements on informed 
consent. To prevent communication errors caused by dif-
ferent reporting mechanisms, a report form has been 
developed specifically for the CBGG proficiency program, 
a copy of which is provided in Figure 1 with examples. The 
proficiency evaluations for platelets and neutrophils are 
distributed among a group of members headed by Vagner 
Castro (Platelet Immunology Laboratory of Hematology 
and Hemotherapy Center of the State University of Campi-
nas, UNICAMP, Campinas, São Paulo, Brazil). Serologic 
confirmation is not mandated by this group because of the 
lack of regulated antisera.
Electronic Data Records and Databases
 Members of the CBGG have recognized the need to 
provide manufacturers of electronic laboratory informa-
tion systems (LIS) with appropriate input as they make 
decisions on changes to their operating systems. Presently, 
LIS do not have place-holder fields for genotype results or 
the capability to compare the DNA test result to the pheno-
type when available. Neither do algorithms exist to make 
phenotype predictions from the DNA test results. The 
CBGG members also discussed that a position paper from 
the CBGG could be developed to outline what users desire 
from manufacturers of DNA testing platforms and what 
nucleotide targets are needed to define a predicted antigen 
phenotype. It was recommended that a focus group be as-
sembled to address LIS user requirements.
Conclusions
 The CBGG is a self-help, not-for-profit organization 
designed as an interactive collaborative for members to 
learn from each other and to strive to achieve excellence 
in molecular testing of blood group, platelet, and neutro-
phil antigens. Anyone interested and willing to contribute 
intellectually is welcome to join. Important information 
on analyte specific reagents in the context of laboratory-
developed tests, decisions on the specifications of infor-
mation systems, and the appropriate targets for molecular 
testing are important topics for discussion in 2010.
Fig. 1. Example of the CBGG proficiency exchange program result 
form.
CBGG Proficiency Exchange Program Result Form 
NOTE: Report results on this Form and use the nucleotide designation from “List of 
Targets…. “ in the current CBGG Document.
Date sent: _________________________  Date due: _________________ 
    Originating Laboratory:   Receiving Laboratory: 
Name:     __________________________  __________________________ 
Address: __________________________  __________________________ 
     __________________________  __________________________ 
     __________________________  __________________________ 
Phone #: __________________________  __________________________ 
Fax #:     __________________________  __________________________ 
DNA Sample ID: _____________ Molecular Assay Requested: [JK*A/B or JK*01/02]










[AS-PCR] [JK*A/JK*B] [Jk(a+b+)] [Signature] [Signature] 
   [Date] [Date]
Comments/Disclaimers: 
Originating (Verification) Laboratory: 







[PCR-RFLP] [JK*A/JK*B] [Jk(a+b+)] [Name] 
   [Date]
Comments/Disclaimers: 
Acknowledgement of verified results: ________________________________________ 
Originating Laboratory: Complete all information for the receiving laboratory to perform testing.  
Testing Laboratory: Fill in testing information; sign and date. Fax form to submitting laboratory. 
Submitting Laboratory:  Fill in results of submitting laboratory, sign and date. Fax verification to 
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ies of Immunohematology for distribution, please send 
request, 4 months in advance, to immuno@usa.
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Manuscripts
The editorial staff of Immunohematology welcomes manuscripts pertaining to blood group serology and educa-
tion for consideration for publication.  We are especially interested in case reports, papers on platelet and white 
cell serology, scientific articles covering original investigations, and papers on new methods for use in the blood 
bank.  Deadlines for receipt of manuscripts for consideration for the March, June, September, and December 
issues are the first weeks in November, February, May, and August, respectively.  For instructions for scientific 
articles, case reports and review articles, see Instructions for Authors in every issue of Immunohematology or on 
the Web at www.redcross.org/immunohematology.  Include fax and phone numbers and e-mail address with all 
articles and correspondence. E-mail all manuscripts to immuno@usa.redcross.org.
For information concerning Immunohematology, 
Journal of Blood Group Serology and Education, or 
the Immunohematology Methods and Procedures 
manual, contact us by e-mail at immuno@usa.
redcross.org.
G.A. Denomme et al.
